Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast cancer receiving chemotherapy. We now present the c...

Full description

Bibliographic Details
Main Authors: Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Breast
Subjects:
Biosimilar
Combination therapy
Efficacy
Metastatic breast cancer
Monotherapy
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621003489

Internet

http://www.sciencedirect.com/science/article/pii/S0960977621003489

Similar Items